Medytox: "US ITC Proves Daewoong Pharmaceutical's Strain Misappropriation with Scientific Evidence" View original image


[Asia Economy Reporter Cho Hyun-ui] Medytox stated on the 10th that the preliminary ruling document on the trade secret infringement lawsuit involving the theft of botulinum strains, released by the U.S. International Trade Commission (ITC), "proved Daewoong Pharmaceutical's strain theft allegations with scientific evidence."


On the same day, Medytox said, "The ITC found that all evidence submitted by both parties supported the fact that Daewoong Pharmaceutical stole Medytox's strains and manufacturing processes," adding, "The claim that Daewoong Pharmaceutical discovered the botulinum strain in soil and independently developed the manufacturing process was also judged to be false."


Medytox emphasized, "The ITC detailed the vast amount of materials submitted by both companies, testimonies from related parties, and experts' strain DNA analysis results," and stated, "Daewoong Pharmaceutical's claim that the ITC inferred trade secret theft based solely on Medytox's unilateral assertions without solid evidence has been proven groundless."


Earlier, on the 6th of last month (local time), the ITC ruled preliminarily in the 'botulinum strain and manufacturing technology theft' case that Daewoong Pharmaceutical infringed Medytox's trade secrets, siding with Medytox. Along with this, the ITC issued a preliminary ruling to ban the import of Daewoong Pharmaceutical's botulinum toxin product Nabota (U.S. product name Jeuveau) for ten years.



About a month later, on the 6th (local time), when the ITC ruling document was disclosed, Daewoong Pharmaceutical rebutted, saying, "It is the height of bias and distortion, and merely a conclusion based on inference without concrete evidence." Daewoong Pharmaceutical stated, "The ITC administrative law judge made an unfair and biased decision far from substantive truth to protect domestic industry," and added, "We will clearly impeach the preliminary decision full of serious errors and definitely win in the final decision in November."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing